Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.
Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.
The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.
AstraZeneca's hope is that the blood test could replace tissue samples and be used to identify patients who could benefit from its lung drugs.
The drug did not hit its Phase III primary target of improving progression-free survival.
The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.
The FDA greenlighted the drug for three cancers.
It's the second for this cancer drug in two weeks.
HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.
The FDA granted Priority Review for consideration of Avastin for some cervical-cancer patients.
Cyramza patients had more favorable overall survival rates than placebo patients, but the differences were not statistically significant.
Bristol-Myers Squibb is moving forward with its FDA filing of PD-1 Opdivo (formerly known as nivolumab) for patients with advanced melanoma who have been previously treated with the BMS drug Yervoy.
UnitedHealthcare finds drug costs more than doubled.
The regulator wants men to be part of breast cancer clinical trials.
An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.
Eli Lilly's gastric cancer drug Cryamza failed to hit its primary Phase III liver cancer target.
August 15 is John Johnson's last day as president and CEO.
The bedside decision-making app includes clinical trial and drug information as well as breaking news.
The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.
Companies including WellPoint and Highmark are deploying financial incentives for doctors to stick with recommended cancer treatments.
The drugmaker has paired up with Incyte and CytomyX in two separate deals.
The companies announced Tuesday that Arzerra, already indicated for leukemia, failed to outdo Roche's Rituxan in the lymphoma setting.
The FDA has granted priority review status for the expanded-indication review.
Pharma has sunk a lot of money into a field that saw $91 billion in sales last year. But those bets come amid turmoil in the US healthcare market, including a tussle over price.
A survey by investment firm Jefferies found that the temporary 2013 suspension had a minimal impact on how doctors perceive the drug.
CEO Ian Read told investors Monday that an AZ merger would benefit Astra shareholders and add oomph to its marketing potential. Another exec said he could "envision" filing palbociclib this year, but made no promises.
The FDA announced Tuesday its approval of lung cancer drug Zykadia for patients with metastatic ALK-positive non-small cell lung cancer.
Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.
US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.
The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.